TSXV - Free Realtime Quote CAD

Kane Biotech Inc. (KNE.V)

0.1000

0.0000

(0.00%)

As of 10:12:07 AM EDT. Market Open.

Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial

Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne VulgarisWINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review Board (“IRB”) of the University of Miami Health System (“UHealth”) to commence a clinical study of Kane’s prototype DispersinB® Acne Cleanser for the treatment of mild to moderate cases of Acne V

GlobeNewswire 29 days ago

KNBIF
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel

Strategic Partnership Expands Access to Innovative Wound Care Solution Across CanadaWINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel Product line. In November 2024, Kane Biotech received Health Canada approval for its revyve™ Antimicrobial Wound Gel, marking a significant milestone for the company

GlobeNewswire last month

KNBIF
Kane Biotech Announces Second and Final Closing of Private Placement Offering

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed the second and final closing of its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the second and final closing of the Offering, Kane issued 4,235,000 Shares at

GlobeNewswire last month

KNBIF
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology

Thursday, January 23rd, 2025 at 4:15pm Eastern TimeWINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, January 23, 2025 at 4:15pm Eastern Time. Participants can register for the webinar by using this link: Kane Webinar – Jan 23, 2025 Marc Edwards, President and CEO, along with Dr. Robert Huizinga, Executive Chairman will update investors as to what they should expect in 2025, building

GlobeNewswire 2 months ago

KNBIF
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed the first closing of its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the first closing Kane issued 12,750,000 Shares at a price of $0.10 per Share for aggreg

GlobeNewswire 2 months ago

KNBIF
Kane Biotech Announces $3,000,000 Private Placement Offering

WINNIPEG, Manitoba, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it intends to undertake a non-brokered private placement offering of up to 30,000,000 common shares of the Company (each a “Share”) at a price of $0.10 per Share for aggregate proceeds of up to $3,000,000 (the “Offering”). The proceeds from the Offering will be used for working capital and general corporate purposes. “We are continuing to build

GlobeNewswire 4 months ago

KNBIF
Kane Biotech Third Quarter 2024 Earnings: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2023)

Kane Biotech ( CVE:KNE ) Third Quarter 2024 Results Key Financial Results Revenue: CA$1.28m (up 79% from 3Q 2023). Net...

Simply Wall St. 4 months ago

KNBIF
Kane Biotech Announces Third Quarter 2024 Financial Results

Company Records First Commercial Sale of revyve™ Wound GelWINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results. Third Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Product sales for the three months ended September 30, 2024 was $597,677 compared to $3,631 in the three months ended September 30

GlobeNewswire 4 months ago

KNBIF
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare GlobalWINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem Technologies Inc. (“BioStem”), has recently signed a Letter of Intent to acquire commercial stage products and development technologies from the Company’s current U.S. distributor, ProgenaCare Global LLC (“Pr

GlobeNewswire 4 months ago

KNBIF
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024

Conference Call to be held on December 3, 2024WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on Thursday, November 28, 2024. Kane Biotech management will host a conference call at 4:30 p.m. ET on December 3, 2024 to review the financial results and discuss business developments in the period. Participants must register for the call using the following link:

GlobeNewswire 4 months ago

KNBIF
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel

WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the Company to immediately start promoting and selling this product in Canada. “We are excited to bring this much needed product to Canada,” said Marc Edwards, President & CEO. “Congratulations to the Kane Biotech team

GlobeNewswire 4 months ago

KNBIF
Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement

President & CEO Marc Edwards and Executive Chair Dr. Robert Huizinga Discuss This Strategic OpportunityWINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that President & CEO, Marc Edwards and Dr. Robert Huizinga, Executive Chair of Kane Biotech have released a video outlining the details and benefits to Kane Biotech and its investors of the FB Dermatology S.R.L. (“FB Dermatology”) transaction which th

GlobeNewswire 4 months ago

KNBIF
Kane Biotech Announces Agreement to Acquire FB Dermatology

Transaction will Strengthen Kane’s Wound Care and Dermatology Portfolio and Expand Global Commercial ReachWINNIPEG, Manitoba, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that it has entered into a binding term sheet (the “Term Sheet”) setting out the key terms and conditions relating to the acquisition of all of the issued and outstanding shares (the “Purchased Shares”) of FB Dermatology S.R.L. (“FB Dermatology”),

GlobeNewswire 4 months ago

KNBIF
Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine

WINNIPEG, Manitoba, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it is donating 2,000 ounces of revyve™ Antimicrobial Wound Gel to the Ukraine medical relief effort. The product will be used to assist in the healing of severe and chronic wounds that tens of thousands of Ukrainian casualties have suffered as a result of the devasting effects of war. “I am humbled by the prospect of assisting the people of Ukraine in their

GlobeNewswire 5 months ago

KNBIF
Positive Signs As Multiple Insiders Buy Kane Biotech Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. 5 months ago

KNBIF
Kane Biotech Announces Exclusive Distribution Agreement With XSONX

WINNIPEG, Manitoba, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed an exclusive five year distribution agreement with XSONX LLC (“XSONX”) for Kane to distribute XSONX’s Wound Hygiene System in Canada, Australia, New Zealand and the Gulf Cooperation Council (GCC) Countries (the “Territories”). The XSONX Wound Hygiene System is a cordless vibrational debridement tool which safely cleans and debrides chronic and

GlobeNewswire 5 months ago

KNBIF
Kane Biotech to Participate in a Multinational Corporate Collaboration Project

WINNIPEG, Manitoba, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to $75,000 in funding through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to collaborate on a research and development project with a multinational corporate partner. The goal of the collaboration project is to develop a Proof-of Concept for its DispersinB®

GlobeNewswire 6 months ago

KNBIF
Kane Biotech Announces Attendance at Upcoming Wound Care Conferences

WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its revyve™ Antimicrobial Wound Gel and revyve™ Antimicrobial Wound Gel Spray products at the following wound care conferences: Symposium on Advanced Wound Care (SAWC) (October 2-5, 2024 in Las Vegas Nevada) where Kane will be presenting research on the antibiofilm properties and compatibility with different dre

GlobeNewswire 6 months ago

KNBIF
Kane Biotech Announces Exercise of Warrants

WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the exercise of an aggregate of 5 million warrants at an exercise price of $0.10 per common share for total proceeds of $500,000. “The shares are being held by some long-term supporters of Kane,” said Marc Edwards, President & CEO. The proceeds from these warrant exercises will be used for general working capital purposes. About Kane Biotech Kane Biotech Inc. is

GlobeNewswire 6 months ago

KNBIF
Kane Biotech Announces Second Quarter 2024 Financial Results

Company Realizes $10.4M Gain on the Sale of STEMWINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its second quarter 2024 financial results. The second quarter 2024 financial results reflect the closing of the sale of STEM which took place on April 12, 2024. The Company recorded a gain of $10,359,882 on this transaction which is offset by income tax loss carry forwards for income tax purpose

GlobeNewswire 7 months ago

KNBIF

Performance Overview

Return	KNE.V	S&P/TSX Composite index (^GSPTSE)
YTD	0.00%	-4.29%
1-Year	-28.57%	+6.58%
3-Year	-9.09%	+8.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kane Biotech Inc. (KNE.V)

Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial

Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel

Kane Biotech Announces Second and Final Closing of Private Placement Offering

Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology

Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering

Kane Biotech Announces $3,000,000 Private Placement Offering

Kane Biotech Third Quarter 2024 Earnings: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2023)

Kane Biotech Announces Third Quarter 2024 Financial Results

Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024

Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel

Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement

Kane Biotech Announces Agreement to Acquire FB Dermatology

Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine

Positive Signs As Multiple Insiders Buy Kane Biotech Stock

Kane Biotech Announces Exclusive Distribution Agreement With XSONX

Kane Biotech to Participate in a Multinational Corporate Collaboration Project

Kane Biotech Announces Attendance at Upcoming Wound Care Conferences

Kane Biotech Announces Exercise of Warrants

Kane Biotech Announces Second Quarter 2024 Financial Results

Performance Overview